Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Rating) – Research analysts at Oppenheimer cut their FY2022 earnings per share (EPS) estimates for shares of Trevi Therapeutics in a research report issued to clients and investors on Monday, November 14th. Oppenheimer analyst L. Gershell now anticipates that the company will post earnings per share of ($0.51) for the year, down from their prior estimate of ($0.49). The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.55) per share. Oppenheimer also issued estimates for Trevi Therapeutics’ Q4 2022 earnings at ($0.09) EPS, Q1 2023 earnings at ($0.09) EPS, Q2 2023 earnings at ($0.10) EPS, Q3 2023 earnings at ($0.10) EPS, Q4 2023 earnings at ($0.11) EPS, FY2023 earnings at ($0.41) EPS, FY2024 earnings at ($0.44) EPS, FY2025 earnings at ($0.39) EPS and FY2026 earnings at ($0.35) EPS.
Trevi Therapeutics (NASDAQ:TRVI – Get Rating) last announced its quarterly earnings results on Thursday, November 10th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.03.
Trevi Therapeutics Stock Performance
Shares of NASDAQ TRVI opened at $2.14 on Thursday. The company has a quick ratio of 5.18, a current ratio of 8.70 and a debt-to-equity ratio of 0.03. The business’s 50 day moving average is $2.06 and its two-hundred day moving average is $2.65. The company has a market cap of $94.31 million, a P/E ratio of -2.74 and a beta of 0.75. Trevi Therapeutics has a 12 month low of $0.46 and a 12 month high of $4.68.
Hedge Funds Weigh In On Trevi Therapeutics
Large investors have recently made changes to their positions in the company. Commonwealth Equity Services LLC bought a new stake in Trevi Therapeutics in the 1st quarter valued at about $33,000. Virtu Financial LLC bought a new position in shares of Trevi Therapeutics in the first quarter worth $44,000. Acuta Capital Partners LLC purchased a new position in Trevi Therapeutics in the second quarter worth $98,000. State Street Corp purchased a new stake in Trevi Therapeutics during the first quarter valued at about $81,000. Finally, Jump Financial LLC bought a new position in Trevi Therapeutics in the third quarter worth about $66,000.
About Trevi Therapeutics
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis.
- Get a free copy of the StockNews.com research report on Trevi Therapeutics (TRVI)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.